Azenta Q1 revenue $178M (+28% YoY); GAAP EPS ($0.15) vs $0.04 prior year; guides Q2 revenue $156-171M

Azenta, Inc.

2023-Q1 EPS reported -$0.15 revenue$178,366,000

Revenue $178M, up 28% YoY; organic growth ex-COVID of 7%.
GAAP diluted EPS from continuing ops ($0.15) vs $0.04 prior year; non-GAAP EPS $0.12 flat YoY.
Life Sciences Products revenue $90M (+80% YoY) driven by B Medical acquisition; Services $89M (-1%).
Q2 FY23 guidance: revenue $156-171M, non-GAAP EPS ($0.04)-$0.04, GAAP EPS ($0.24)-($0.16).
Initiated cost cuts targeting 2 points margin improvement in 2H FY23; completed Ziath acquisition on Feb 2, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Azenta, Inc. reported first quarter ended December 31, 2022 results: revenue $178 million, EPS $ (0.15). Guidance initiated.

Period: first quarter ended December 31, 2022
Revenue: $178 million
EPS: $ (0.15)
Guidance: initiated
Result: reported results

Exact text from the filing

● Reported Q1’23 Revenue of $178 Million and Growth of 28% Year-Over-Year

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Azenta, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-001046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.